Issue Cover

Press Releases

Breaking news from across the pharma sector

Articles

 CryoLogyx Completes £500k Seed Funding Round
CryoLogyx Completes £500k Seed Funding Round

CryoLogyx, a University of Warwick spinout redefining cell technology through cryopreservation, today announced the close of its oversubscribed seed funding round. The £500k GBP investment came from private UK business angels and the Wider Oxford Technology Angel Network (WOTAN), which includes previous investors Oxford Technology Management.

18 March 2024Press Releases
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASDAQ: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to expand its in-house high-throughput screening tools.

18 March 2024Press Releases
SGD Pharma successfully trials hydrogen burners at its Saint-Quentin-Lamotte (SQLM) plant to acceler
SGD Pharma successfully trials hydrogen burners at its Saint-Quentin-Lamotte (SQLM) plant to acceler

March 12th, 2024 – At the end of January, SGD Pharma, a global leader in glass primary packaging for the pharmaceutical industry, started a two-week trial using 100% hydrogen burners for industrial-scale glass production.

12 March 2024Press Releases
Extended live cell imaging at nanoscale resolution
Extended live cell imaging at nanoscale resolution

Leica Microsystems, a leader in microscopy and scientific instrumentation, has revealed TauSTED Xtend, a new STED microscopy approach that enables extended multicolor live cell imaging at nanoscopic resolution. By combining spatial and lifetime information, TauSTED Xtend resolves details of live or intact specimens at nanoscale. At the same time, the access to that extra level of information allows working at extremely low light dose

12 March 2024Press Releases
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna). Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.

11 March 2024Press Releases
 PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand
PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand

Manchester, United Kingdom, 29th February 2024 – PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University.

5 March 2024Press Releases
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced successful completion of Good Manufacturing Practice (“GMP”) manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate.

5 March 2024Press Releases
ADARE PHARMA SOLUTIONS TO EXPAND PACKAGING & WAREHOUSING CAPABILITIES IN EUROPE LAWRENCEVILLE, NJ
ADARE PHARMA SOLUTIONS TO EXPAND PACKAGING & WAREHOUSING CAPABILITIES IN EUROPE LAWRENCEVILLE, NJ

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced that work has begun to add packaging capabilities and further warehousing capacity at its Pessano facility in Milan, Italy.

5 March 2024Press Releases
CluePoints’ Audit Trail Review Project Wins Award for Innovation in the Management of Clinical Data
CluePoints’ Audit Trail Review Project Wins Award for Innovation in the Management of Clinical Data

CluePoints, providers of best-in-class statistical and AI-driven software solutions, has won the 2024 Annual Association of Clinical Data Management (ACDM24) Innovation in the Management of Clinical Data Award.

5 March 2024Press Releases
SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal
SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal

: SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase

4 March 2024Press Releases
  Optibrium Launches a Metabolism Prediction Software Platform Tailored to DMPK Scientists
Optibrium Launches a Metabolism Prediction Software Platform Tailored to DMPK Scientists

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the launch of Semeta™, a metabolism prediction platform tailored specifically for drug metabolism and pharmacokinetics (DMPK) scientists. Fundamental to improving a drug’s chance of clinical success, Semeta allows the accurate prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery, with superior precision to comparable software.

27 February 2024Press Releases
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits
Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits

February 27, 2024 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. The kits provide rapid, cost-

27 February 2024Press Releases